|
gptkbp:instanceOf
|
gptkb:brand
gptkb:drug
|
|
gptkbp:activeIngredient
|
gptkb:semaglutide
|
|
gptkbp:administrationInstruction
|
take on empty stomach
take with small amount of water
wait at least 30 minutes before eating or drinking
|
|
gptkbp:approvalYear
|
2019
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:associatedWith
|
gptkb:Ozempic
gptkb:Wegovy
|
|
gptkbp:ATCCode
|
gptkb:A10BJ06
|
|
gptkbp:compatibleWith
|
gptkb:diabetic_ketoacidosis
type 1 diabetes
|
|
gptkbp:contraindication
|
gptkb:multiple_endocrine_neoplasia_syndrome_type_2
personal or family history of medullary thyroid carcinoma
|
|
gptkbp:drugClass
|
GLP-1 receptor agonist
|
|
gptkbp:effect
|
lowers blood glucose
promotes weight loss
|
|
gptkbp:firstOralGLP1
|
true
|
|
gptkbp:form
|
gptkb:tablet
14 mg
3 mg
7 mg
|
|
gptkbp:genericAvailable
|
false
|
|
gptkbp:halfLife
|
about 1 week
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Rybelsus
|
|
gptkbp:manufacturer
|
gptkb:Novo_Nordisk
|
|
gptkbp:marketedIn
|
gptkb:Canada
gptkb:European_Union
gptkb:Japan
gptkb:United_States
|
|
gptkbp:mechanismOfAction
|
GLP-1 receptor agonist
|
|
gptkbp:pregnancyCategory
|
not recommended
|
|
gptkbp:prescriptionRequired
|
https://www.rybelsus.com/
|
|
gptkbp:prescriptionStatus
|
prescription only
|
|
gptkbp:riskFactor
|
pancreatitis
hypoglycemia (when used with other antidiabetics)
thyroid C-cell tumors (in rodents)
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
vomiting
diarrhea
abdominal pain
decreased appetite
|
|
gptkbp:storage
|
store at room temperature
|
|
gptkbp:usedFor
|
gptkb:type_2_diabetes
|
|
gptkbp:bfsParent
|
gptkb:Novo_Nordisk
gptkb:Mounjaro
gptkb:司美格鲁肽
|
|
gptkbp:bfsLayer
|
6
|